Literature DB >> 7373538

Biological disposition of sodium dichloroacetate in animals and humans after intravenous administration.

G Lukas, K H Vyas, S D Brindle, A R Le Sher, W E Wagner.   

Abstract

Sodium dichloroacetate, a potential antidote for lactic acidosis, was administered intravenously to rats, dogs, and four humans. In three rats, maximum plasma sodium dichloroacetate concentrations were 120-164 microgram/ml after a 100-mg/kg dose and declined with half-lives of 2.1-4.4 hr. In two dogs, maximal concentrations of 447 and 508 microgram/ml were attained after a 100-mg/kg dose. The subsequent decline was relatively slow with approximate half-lives of 17.1 and 24.6 hr. An intravenous infusion of 10 mg/kg was administered over 20 min to two human subjects. Two other subjects received 20 mg/kg. After the infusion, maximum plasma concentrations of 19.9 and 24.7 microgram/ml were seen with the lower dose and 57.3 and 74.9 microgram/ml were achieved with the higher dose. Thereafter, concentrations declined rapidly with half-lives of 20-36 min. The observed large interspecies differences in half-lives could be explained in terms of differences in the apparent volume of distribution and/or clearance.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7373538     DOI: 10.1002/jps.2600690415

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  11 in total

1.  Treatment of chronic congenital lactic acidosis by oral administration of dichloroacetate.

Authors:  Y Kuroda; M Ito; K Toshima; E Takeda; E Naito; T J Hwang; T Hashimoto; M Miyao; M Masuda; K Yamashita
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

2.  The acetyl group deficit at the onset of contraction in ischaemic canine skeletal muscle.

Authors:  Paul A Roberts; Susan J G Loxham; Simon M Poucher; Dumitru Constantin-Teodosiu; Paul L Greenhaff
Journal:  J Physiol       Date:  2002-10-15       Impact factor: 5.182

3.  Haemodialysis studies with dichloroacetate.

Authors:  S H Curry; A Lorenz; G N Henderson; D R Mars; P W Stacpoole
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  Dichloroacetate attenuates neuronal damage in a gerbil model of brain ischemia.

Authors:  R V Dimlich; P J Marangos
Journal:  J Mol Neurosci       Date:  1994       Impact factor: 3.444

5.  Metabolic effects and pharmacokinetics of intravenously administered dichloroacetate in humans.

Authors:  P G Wells; G W Moore; D Rabin; G R Wilkinson; J A Oates; P W Stacpoole
Journal:  Diabetologia       Date:  1980-08       Impact factor: 10.122

Review 6.  Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment.

Authors:  H J Clewell; P R Gentry; T R Covington; J M Gearhart
Journal:  Environ Health Perspect       Date:  2000-05       Impact factor: 9.031

7.  Dichloroacetate affects proliferation but not apoptosis in canine mammary cell lines.

Authors:  Tatjana P Harting; Mandy Stubbendorff; Susanne C Hammer; Patrik Schadzek; Anaclet Ngezahayo; Hugo Murua Escobar; Ingo Nolte
Journal:  PLoS One       Date:  2017-06-07       Impact factor: 3.240

8.  Gender-Related Effect of Sodium Dichloroacetate on the Number of Hassall's Corpuscles and RNA NKCC1 Expression in Rat Thymus.

Authors:  Jūratė Stanevičiūtė; Milda Juknevičienė; Ingrida Balnytė; Angelija Valančiūtė; Vaiva Lesauskaitė; Julija Fadejeva; Rimantas Stakauskas; Donatas Stakišaitis
Journal:  Biomed Res Int       Date:  2019-04-24       Impact factor: 3.411

Review 9.  The Importance of Gender-Related Anticancer Research on Mitochondrial Regulator Sodium Dichloroacetate in Preclinical Studies In Vivo.

Authors:  Donatas Stakišaitis; Milda Juknevičienė; Eligija Damanskienė; Angelija Valančiūtė; Ingrida Balnytė; Marta Maria Alonso
Journal:  Cancers (Basel)       Date:  2019-08-20       Impact factor: 6.639

10.  Low-dose pharmacokinetics and oral bioavailability of dichloroacetate in naive and GST-zeta-depleted rats.

Authors:  Shakil A Saghir; Irvin R Schultz
Journal:  Environ Health Perspect       Date:  2002-08       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.